Back

Human BDNF ELISA Kit0 Publications

Catalog number: KE00096

Be the first to review this product

$399.00

Freight/Packing £00.00

Size: 09µ/gram

Please visit your regions distributor:

Request quote for
bulk/custom formulations

Images See all

Overview

Product name:
Human BDNF ELISA Kit
Tests:
1 X 96 well plate
Sample type:
Serum, Plasma, Cell culture supernatant
Assay type:
Sandwich
Sensitivity:
0.1 pg/mL
Range:
12.5 - 800 pg/mL
Reacted Species:
Human
Tested applications:
Sandwich ELISA
Recovery:
Sample TypeAverageRange
Cell culture supernatant 90% 73%-113%
Human plasma 92% 74%-117%
IntraAssay:
Samplenmean ( pg/mL)SDCV%
1 20 35.8 2.3 6.3
2 20 116.5 9.2 7.9
3 20 513.9 36.9 7.2
InterAssay:
Samplenmean ( pg/mL)SDCV%
1 24 32.2 2.6 8.1
2 24 108.6 8.2 7.6
3 24 517.3 40.8 7.9
Product overview:
KE00096 is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (Sandwich ELISA). The BDNF ELISA kit is to be used to detect and quantify protein levels of endogenous BDNF. The assay recognizes human BDNF. A polyclonal antibody specific for BDNF has been pre-coated onto the microwells. The BDNF protein in samples is captured by the coated antibody after incubation. Following extensive washing, a monoclonal antibody specific for BDNF is added to detect the captured BDNF protein. For signal development, horseradish peroxidase (HRP)-conjugated Anti-mouse antibody is added, followed by Tetramethyl-benzidine (TMB) reagent. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.

Properties

Storage Instructions:
All the reagents are stored at 2-8℃. Refer to the protocol for further storage instructions.
Synonyms:
Abrineurin, BDNF
Background

The brain-derived neurotrophic factor (BDNF), as a member of the neurotrophin family of growth factors, is broadly expressed in the central nervous system. BDNF is involved in cerebral morphogenesis, synaptic plasticity and learning, mental health, degenerative central nervous system (CNS) diseases, and energy metabolism. BDNF has recently been identified as one of the four major pharmaceutical targets in neuropsychiatric diseases, including depression and bipolar disorder. In addition, BDNF is increasingly considered as a potential therapeutic agent for neurodevelopmental disorders such as Rett syndrome.


Back
to top